Streetbeat News

ACON

Aclarion, Inc.

https://www.aclarion.com

Industry

Medical - Healthcare Information Services

Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California.

Open

0.20

Mkt cap

1.9M

Volume

673K

High

0.20

P/E Ratio

-0.05

52-wk high

7.39

Low

0.19

Div yield

N/A

52-wk low

0.16

Aclarion, Inc. has been granted an Australian patent (No. 2021254588) for a Magnetic Resonance (MR) Spectroscopy System and Method for diagnosing painful and non-painful intervertebral discs. This patent could potentially enhance Aclarion's product offerings and market reach in the medical diagnostics field, particularly in the area of back pain diagnosis.

Portfolio Pulse from Benzinga Newsdesk

January 18, 2024 | 6:02 pm

Aclarion, Inc. (NASDAQ: ACON, ACONW) has announced the release of Nociscan 2.6, which expands the compatibility of its augmented intelligence platform to additional MRI scanners beyond Siemens. This development is expected to increase access to Nociscan for healthcare providers and patients globally, addressing chronic low back pain which affects approximately 266 million people. The company aims to make Nociscan the standard tool for diagnosing and treating chronic low back pain.

Portfolio Pulse from Benzinga Newsdesk

January 17, 2024 | 1:23 pm

In Friday's after-market session, several healthcare stocks experienced significant movements. Aclarion (ACON) led the gainers with a 21.6% rise, while Atreca (BCEL) saw the largest decline among the losers, dropping 21.4%. Other notable movers included Outset Medical (OM), Absci (ABSI), and Cara Therapeutics (CARA) with positive gains, and Estrella Immunopharma (ESLA), Nektar Therapeutics (NKTR), and Revelation Biosciences (REVB) with declines.

Portfolio Pulse from Benzinga Insights

January 12, 2024 | 9:31 pm

Aclarion, Inc. (NASDAQ:ACON) stock is trading higher after announcing a strategic partnership with Alphatec Spine, Inc., a subsidiary of Alphatec Holdings, Inc. (NASDAQ:ATEC). The partnership aims to evaluate the Nociscan technology and co-market it. Aclarion's trading volume surged, with over 15.7 million shares traded, compared to a 100-day average of less than 174,000. Aclarion had a 1-for-16 reverse stock split on Jan. 3, and shares are currently up 64% at $5.02.

Portfolio Pulse from Erica Kollmann

January 08, 2024 | 3:08 pm

Aclarion, Inc. (ACON) shares have risen following the announcement of a partnership agreement with Alphatec Spine, Inc. This partnership is expected to be beneficial for Aclarion as it may lead to increased exposure and potential revenue growth through collaboration with Alphatec Spine, a company specializing in the design and development of spinal surgery products.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 2:53 pm

Aclarion, Inc. shares have resumed trading. There is no additional context provided regarding the reason for the trading halt or any other events that might influence the stock price.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 4:23 pm

Shares of Aclarion, Inc. were halted due to a circuit breaker after experiencing a significant upside, with the stock price surging by 12.6%.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 4:17 pm

Shares of Aclarion, Inc. were halted due to a circuit breaker after the stock price dropped by 11.2%. This sudden decline in share price triggered the market's automatic stop mechanism to prevent further immediate losses.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 3:06 pm

Trading for ACON was halted and then resumed at 8:55 AM ET, with an update on news and resumption times provided.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 1:55 pm

Trading on ACON was halted at 7:50:00 p.m. ET due to pending news. The halt is in place to ensure a fair and orderly market until the news is released.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 12:50 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.